Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 12/20 | 0.64 |
| ▸ | KDR | P35968 | 12/20 | 0.64 |
| ▸ | MET | P08581 | 3/20 | 0.63 |
| ▸ | FLT3 | P36888 | 1/20 | 0.59 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.59 |
| ▸ | AXL | P30530 | 3/20 | 0.59 |
| ▸ | KIT | P10721 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22104477 | 0.92 | PDGFRA (0.63) | PDGFRAKDRMETFLT3AURKB | |
| SCHEMBL5824830 | 0.85 | PDGFRA (0.66) | PDGFRAKDRMETFLT3AURKB | |
| SCHEMBL22104449 | 0.85 | PDGFRA (0.65) | PDGFRAKDRMETKIT | |
| SCHEMBL22104150 | 0.84 | MET (0.63) | PDGFRAKDRMETFLT3AURKB | |
| SCHEMBL23835028 | 0.82 | PDGFRA (0.74) | PDGFRAKDRMETFLT3AURKB | |
| SCHEMBL29438545 | 0.82 | PDGFRA (0.74) | PDGFRAKDRMETFLT3AURKB | |
| SCHEMBL28708722 | 0.82 | PDGFRA (0.74) | PDGFRAKDRMETFLT3AURKB | |
| SCHEMBL5825872 | 0.81 | PDGFRA (0.55) | PDGFRAKDRMETFLT3AURKB | |
| SCHEMBL1877070 | 0.81 | PDGFRA (0.84) | PDGFRAKDRMETAXLKIT | |
| SCHEMBL5825004 | 0.81 | PDGFRA (0.79) | PDGFRAKDRMETFLT3AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4491181-A1 | NOVEL USE OF QUINOLINE COMPOUND | Tarapeutics Science Inc. (CN) | 2025-01-15 | — | — | EP | disclosed |
| CN-116763787-A | New application of quinoline compound | 安徽中科拓苒药物科学研究有限公司 | 2023-09-19 | — | — | CN | disclosed |
| WO-2023168740-A1 | NOVEL USE OF QUINOLINE COMPOUND | 安徽中科拓苒药物科学研究有限公司 | 2023-09-14 | — | — | WO | disclosed |
| CN-111303024-B | Quinoline-structured pan-KIT kinase inhibitor and application thereof | 安徽中科拓苒药物科学研究有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-20220064117-A1 | PAN-KIT KINASE INHIBITOR HAVING QUINOLINE STRUCTURE AND APPLICATION THEREOF | Tarapeutics Science Inc. (CN) | 2022-03-03 | — | — | US | disclosed |
| EP-3896059-A1 | PAN-KIT KINASE INHIBITOR HAVING QUINOLINE STRUCTURE AND APPLICATION THEREOF | Tarapeutics Science Inc. (CN) | 2021-10-20 | — | — | EP | disclosed |
| CN-111303024-A | Quinoline-structured pan-KIT kinase inhibitor and application thereof | 安徽中科拓苒药物科学研究有限公司 | 2020-06-19 | — | — | CN | disclosed |
| WO-2020118753-A1 | PAN-KIT KINASE INHIBITOR HAVING QUINOLINE STRUCTURE AND APPLICATION THEREOF | 安徽中科拓苒药物科学研究有限公司 | 2020-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220064117-A1 | PAN-KIT KINASE INHIBITOR HAVING QUINOLINE STRUCTURE AND APPLICATION THEREOF | KIT, MAP3K7, ABL1 | PDGFRA 747/4885KDR 357/4885MET 1150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.